141 related articles for article (PubMed ID: 31902521)
1. Normal brain aging and Alzheimer's disease are associated with lower cerebral pH: an in vivo histidine
Lyros E; Ragoschke-Schumm A; Kostopoulos P; Sehr A; Backens M; Kalampokini S; Decker Y; Lesmeister M; Liu Y; Reith W; Fassbender K
Neurobiol Aging; 2020 Mar; 87():60-69. PubMed ID: 31902521
[TBL] [Abstract][Full Text] [Related]
2. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging.
Meyerhoff DJ; MacKay S; Constans JM; Norman D; Van Dyke C; Fein G; Weiner MW
Ann Neurol; 1994 Jul; 36(1):40-7. PubMed ID: 8024260
[TBL] [Abstract][Full Text] [Related]
3. Hippocampal proton MR spectroscopy in early Alzheimer's disease and mild cognitive impairment.
Foy CM; Daly EM; Glover A; O'Gorman R; Simmons A; Murphy DG; Lovestone S
Brain Topogr; 2011 Oct; 24(3-4):316-22. PubMed ID: 21298332
[TBL] [Abstract][Full Text] [Related]
4. Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Weiss U; Bacher R; Vonbank H; Kemmler G; Lingg A; Marksteiner J
J Clin Psychiatry; 2003 Mar; 64(3):235-42. PubMed ID: 12716263
[TBL] [Abstract][Full Text] [Related]
5. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
MacKay S; Meyerhoff DJ; Constans JM; Norman D; Fein G; Weiner MW
Arch Neurol; 1996 Feb; 53(2):167-74. PubMed ID: 8639067
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
García Santos JM; Gavrila D; Antúnez C; Tormo MJ; Salmerón D; Carles R; Jiménez Veiga J; Parrilla G; Torres del Río S; Fortuna L; Navarro C
Dement Geriatr Cogn Disord; 2008; 26(1):15-25. PubMed ID: 18566544
[TBL] [Abstract][Full Text] [Related]
7. Altered brain high-energy phosphate metabolism in mild Alzheimer's disease: A 3-dimensional
Rijpma A; van der Graaf M; Meulenbroek O; Olde Rikkert MGM; Heerschap A
Neuroimage Clin; 2018; 18():254-261. PubMed ID: 29876246
[TBL] [Abstract][Full Text] [Related]
8. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease.
Pfefferbaum A; Adalsteinsson E; Spielman D; Sullivan EV; Lim KO
Arch Gen Psychiatry; 1999 Feb; 56(2):185-92. PubMed ID: 10025444
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance spectroscopy as a predictor of conversion of mild cognitive impairment to dementia.
Targosz-Gajniak MG; Siuda JS; Wicher MM; Banasik TJ; Bujak MA; Augusciak-Duma AM; Opala G
J Neurol Sci; 2013 Dec; 335(1-2):58-63. PubMed ID: 24035276
[TBL] [Abstract][Full Text] [Related]
10. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Pina MA
Am J Psychiatry; 2005 Apr; 162(4):667-75. PubMed ID: 15800137
[TBL] [Abstract][Full Text] [Related]
11. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Frederick BD; Lyoo IK; Satlin A; Ahn KH; Kim MJ; Yurgelun-Todd DA; Cohen BM; Renshaw PF
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1313-22. PubMed ID: 15588758
[TBL] [Abstract][Full Text] [Related]
12. 1H MR spectroscopy in common dementias.
Kantarci K; Petersen RC; Boeve BF; Knopman DS; Tang-Wai DF; O'Brien PC; Weigand SD; Edland SD; Smith GE; Ivnik RJ; Ferman TJ; Tangalos EG; Jack CR
Neurology; 2004 Oct; 63(8):1393-8. PubMed ID: 15505154
[TBL] [Abstract][Full Text] [Related]
13. Using proton magnetic resonance spectroscopy to identify mild cognitive impairment.
Wang T; Xiao S; Li X; Ding B; Ling H; Chen K; Fang Y
Int Psychogeriatr; 2012 Jan; 24(1):19-27. PubMed ID: 21676281
[TBL] [Abstract][Full Text] [Related]
14. Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease.
Mandal PK; Akolkar H; Tripathi M
J Alzheimers Dis; 2012; 31 Suppl 3():S75-86. PubMed ID: 22426021
[TBL] [Abstract][Full Text] [Related]
15. Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Watanabe T; Shiino A; Akiguchi I
Dement Geriatr Cogn Disord; 2008; 26(1):89-100. PubMed ID: 18617735
[TBL] [Abstract][Full Text] [Related]
16. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease.
Hattori N; Abe K; Sakoda S; Sawada T
Neuroreport; 2002 Jan; 13(1):183-6. PubMed ID: 11924885
[TBL] [Abstract][Full Text] [Related]
17. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease.
Ackl N; Ising M; Schreiber YA; Atiya M; Sonntag A; Auer DP
Neurosci Lett; 2005 Aug 12-19; 384(1-2):23-8. PubMed ID: 15905028
[TBL] [Abstract][Full Text] [Related]
18. Various MRS application tools for Alzheimer disease and mild cognitive impairment.
Gao F; Barker PB
AJNR Am J Neuroradiol; 2014 Jun; 35(6 Suppl):S4-11. PubMed ID: 24742809
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex.
Mihara M; Hattori N; Abe K; Sakoda S; Sawada T
Neuroreport; 2006 Mar; 17(4):413-6. PubMed ID: 16514368
[TBL] [Abstract][Full Text] [Related]
20. Whole-brain patterns of (1)H-magnetic resonance spectroscopy imaging in Alzheimer's disease and dementia with Lewy bodies.
Su L; Blamire AM; Watson R; He J; Hayes L; O'Brien JT
Transl Psychiatry; 2016 Aug; 6(8):e877. PubMed ID: 27576166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
